Physician profile
Krunalkumar Patel
NPI 1124589213
$1,325.51
in general payments reported to CMS, 2019-2025
13 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $138 · 2024: $669 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.03 |
| Education | $281.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $281.47 | 2024-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $162.39 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $137.14 | 2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $123.48 | 2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $119.40 | 2022-2024 | Farxiga, Lokelma |
| Boston Scientific Corporation | $89.04 | 2022 | |
| Pfizer INC. | $86.30 | 2023-2024 | |
| Amgen INC. | $85.41 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.89 | 2025 | Lifevest |
| Lantheus Medical Imaging, INC. | $62.83 | 2022-2024 | Definity |
| Merck Sharp & Dohme LLC | $46.69 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $41.76 | 2024-2025 | |
| Edwards Lifesciences Corporation | $21.71 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krunalkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.